Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Next Generation Sequencing from small sizes of paired normal and glioblastoma patient tissues

ABSTRACT: Next Generation Sequencing from small sizes of paired normal and glioblastoma patient tissues

PROVIDER: PRJNA765593 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR16019044_1.fastq.gz	Fastqsanger.gz
	SRR16019044_2.fastq.gz	Fastqsanger.gz
	SRR16019045_1.fastq.gz	Fastqsanger.gz
	SRR16019045_2.fastq.gz	Fastqsanger.gz
	SRR16019046_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Next Generation Sequencing from small sizes of paired normal and glioblastoma patient tissues

Project description:Although multi-omics studies of glioblastoma (GBM) have improved understanding of its biology nature and accelerated targeted therapy, data for paired adjacent normal tissues remains limited. Here, we report transcriptomes from 2 paired and 1 non-paired tumor and adjacent normal tissues (NAT) of glioblastoma (GBM) patients sequenced using Illumina Novaseq platform, and 150 bp paired-end reads were generated. This dataset provides a resource of paired GBM and normal tissues to identify novel tumor-specific oncogenes or tumor-suppressor genes.

2023-10-01 | GSE184643 | GEO

Proteomes from small sizes of paired normal and glioblastoma patient tissues

Project description:Although multi-omics studies of glioblastoma (GBM) have improved understanding of its biology nature and accelerated targeted therapy, data for paired adjacent normal tissues (NAT) remains limited. Here, we report proteomes from 3 paired of tumor tissues and NATs of glioblastoma (GBM) patients using liquid chromatography with tandem mass spectrometry (LC-MS/MS)-based label-free quantification. This dataset provides a resource of paired GBM and normal tissues to identify novel tumor-specific oncogenes or tumor-suppressor genes.

2021-09-24 | PXD028730 |

Multi-omics profiling of paired primary and recurrent glioblastoma patient tissues

Project description:Background Despite maximal therapy with surgery, chemotherapy and radiotherapy, glioblastoma multiforme (GBM) patients have a median survival of only 15 months. Almost all patients inevitably experience symptomatic tumor recurrence. A hallmark of this tumor type is the large heterogeneity between patients and within tumors itself which relate to failure of standardized tumor treatment. In this study, tissue samples of paired primary and recurrent GBM tumors were investigated to identify individual factors related to tumor progression. Methods Paired primary and recurrent GBM tumor tissues from 8 patients were investigated with a multi-omics approach using transcriptomics, proteomics and phosphoproteomics. Results In the studied patient cohort, large variations between and within patients are observed for all omics analyses. A few pathways affected at the different omics levels partly overlapped if patients are analyzed at the individual level, such as synaptogenesis (containing the SNARE complex) and cholesterol metabolism. Phosphoproteomics revealed increased STMN1(S38) phosphorylation that relates to ERBB4 signaling. A pathway tool has been developed to visualize and compare the different omics datasets per patient and showed potential therapeutic drugs, such as abobotulinumtoxina and afatinib, that target these affected pathways. Afatinib targeting ERBB4 signaling is currently in clinical trials for GBM. Conclusions Large variation on all omics levels exist between and within GBM patients. Therefore, it will be rather unlikely to find a drug treatment that would fit all patients. Instead a multi-omics approach can be used to identify affected pathways on the individual patient level and select potential treatment options.

2020-11-17 | PXD017952 | Pride

Differential expressed miRNAs between tumor tissues and adjecent normal tissues from a patient with glioblastoma

Project description:Glioblastoma is the most aggressive and lethal malignant brain tumor. miRNA expression profiling could be useful in improving the classification of tumors and predicting their behavior. In this study, the miRNA expression patterns in glioblastoma tumor tissues and adjacent normal tissues were identified through expression profiling of a patient with glioblastoma. The results will hopefully enhance our understandings of the epigentic changes in glioblastoma progression and provide candidates for miRNAs-based targeting tharapy. A paired miRNAs tumor tissues and adjacent tissues of a glioblastoma patient was used in this study. miRNAs were isolated using miRNeasy FFPE Kit (Qiagen). Profiling was established by applying the Agilent human miRNA Microarray (8 M-CM-^W 60K, v16.0) (Agilent Technologies).

2014-09-17 | E-GEOD-61445 | biostudies-arrayexpress

Differential expressed miRNAs between tumor tissues and adjecent normal tissues from a patient with glioblastoma

2014-09-17 | GSE61445 | GEO

Multiomics profiling of paired primary and recurrent glioblastoma patient tissues.

Project description:BackgroundDespite maximal therapy with surgery, chemotherapy, and radiotherapy, glioblastoma (GBM) patients have a median survival of only 15 months. Almost all patients inevitably experience symptomatic tumor recurrence. A hallmark of this tumor type is the large heterogeneity between patients and within tumors itself which relates to the failure of standardized tumor treatment. In this study, tissue samples of paired primary and recurrent GBM tumors were investigated to identify individual factors related to tumor progression.MethodsPaired primary and recurrent GBM tumor tissues from 8 patients were investigated with a multiomics approach using transcriptomics, proteomics, and phosphoproteomics.ResultsIn the studied patient cohort, large variations between and within patients are observed for all omics analyses. A few pathways affected at the different omics levels partly overlapped if patients are analyzed at the individual level, such as synaptogenesis (containing the SNARE complex) and cholesterol metabolism. Phosphoproteomics revealed increased STMN1(S38) phosphorylation as part of ERBB4 signaling. A pathway tool has been developed to visualize and compare different omics datasets per patient and showed potential therapeutic drugs, such as abobotulinumtoxinA (synaptogenesis) and afatinib (ERBB4 signaling). Afatinib is currently in clinical trials for GBM.ConclusionsA large variation on all omics levels exists between and within GBM patients. Therefore, it will be rather unlikely to find a drug treatment that would fit all patients. Instead, a multiomics approach offers the potential to identify affected pathways on the individual patient level and select treatment options.

| S-EPMC7415260 | biostudies-literature

Paired Human Glioblastoma Pre and Post Avastin Treatment

Project description:Paired samples of resected tumor from glioblastoma patients: Pre and post Avastin-treatment samples for each patient in the cohort.

2012-09-30 | E-MEXP-3296 | biostudies-arrayexpress

Multi-omics RNA profiling of glioblastoma patient tissues

Project description:Multi-omics profiling of paired primary and recurrent glioblastoma patient tissues

| EGAD00010001895 | EGA

Gene expression profiling of patient derived glioblastoma tumor tissues

Project description:To study the gene expression profile of patient derived glioblastoma tissues and perform cross platform analysis with metabolite data derived from matching tissues

2019-12-01 | E-MTAB-7116 | biostudies-arrayexpress

Expression profile in hepatocellular carcinoma patient paired tissues

Project description:Expression profile in hepatocellular carcinoma patient paired tissues

| PRJNA656726 | ENA